U.S. Markets close in 3 hrs 7 mins
  • S&P 500

    3,470.86
    -12.95 (-0.37%)
     
  • Dow 30

    28,528.01
    -78.30 (-0.27%)
     
  • Nasdaq

    11,642.73
    -28.83 (-0.25%)
     
  • Russell 2000

    1,637.33
    +3.52 (+0.22%)
     
  • Crude Oil

    41.01
    +0.13 (+0.32%)
     
  • Gold

    1,913.00
    +6.60 (+0.35%)
     
  • Silver

    24.73
    +0.32 (+1.31%)
     
  • EUR/USD

    1.1790
    +0.0062 (+0.5305%)
     
  • 10-Yr Bond

    0.7590
    +0.0150 (+2.02%)
     
  • Vix

    28.02
    +0.61 (+2.23%)
     
  • GBP/USD

    1.2986
    +0.0078 (+0.6013%)
     
  • USD/JPY

    105.4110
    +0.0170 (+0.0161%)
     
  • BTC-USD

    11,761.14
    +704.13 (+6.37%)
     
  • CMC Crypto 200

    239.92
    +6.26 (+2.68%)
     
  • FTSE 100

    5,884.65
    -34.93 (-0.59%)
     
  • Nikkei 225

    23,671.13
    +260.50 (+1.11%)
     

Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

·1 min read

HAMILTON, ON and BOSTON, Sept. 10, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Thursday, September 17, 2020 at 11:00am EDT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., Chief Financial Officer John Crowley, and Chief Medical Officer James O'Leary, M.D.

(PRNewsfoto/Fusion Pharmaceuticals Inc.)
(PRNewsfoto/Fusion Pharmaceuticals Inc.)

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-morgan-stanley-virtual-18th-annual-global-healthcare-conference-301127433.html

SOURCE Fusion Pharmaceuticals Inc.